162 results about "Human dna" patented technology

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

The invention provides methods and compositions for generating non-human transgenic animals that are humanized at one or more gene sequences. According to the methods of the invention, a DNA construct containing a human DNA sequence flanked by sequences from the non-human animal is generated by recombination in a bacterial cell, for example, in E. coli. The DNA construct that is produced can then be introduced into a non-human embryogenic stem cell where it can recombine with the genomic DNA of the non-human animal.

Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that inhibit human DNA ligases.

The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Provided is a method for obtaining human DNA for genetic analysis, by taking the epidermis of testee by means of an adhesive sheet, and by extracting DNA from the epidermis stuck on the adhesive sheet. Provided are also combined sheets for conveniently storing DNA and a kit for taking the epidermis and analyzing DNA. Along with the kits, the method allows DNA to be easily obtained and stably stored for a long period of time. In addition, both the identification and the DNA analysis of a testee can be conducted at the same time by taking epidermal scraps from the testee, along with a figured epidermal print.

Kits and methods providing measurement of tumor burden in a patient derived xenograft (PDX) mouse are described. Exemplary embodiments contemplate taking a sample, typically a blood sample, from a PDX mouse and using a real-time polymerase chain reaction (PCR) system to quantitate both human patient circulating tumor DNA (ctDNA) and mouse DNA. In preferred embodiments, both PCR amplifications are done simultaneously in a multiplex, and a highly polymorphic human DNA target sequence is amplified for high sensitivity, allowing for small volume samples, typically 50-100 μL, of mouse blood. Serial evaluations are possible because the mouse can survive withdrawal of these small volumes of blood. A related method allows for quantitation of ctDNA in the presence of human immune cells added to a “humanized” mouse. These relatively quick and easy methods of determining tumor burden in PDX mice can have predictive value for the efficacy of cancer treatments in human patients.

The invention provides a kit for early stage colorectal cancer auxiliary diagnosis and a use method and a detection system thereof. The kit comprises a nucleic acid isolation and purification reagent, a DNA (deoxyribonucleic acid) sulfite conversion reagent, a KRAS (kirsten rat sarcoma viral oncogene homolog) gene mutation detection reagent, a BMP3 (bone morphogenetic protein 3) and NDRG4 (N-myc downsteam regulated gene 4) gene methylation detection reagent and a fecal occult blood detection reagent, wherein the nucleic acid isolation and purification reagent is used for separating and purifying the human DNA in a faeces sample; the DNA sulfite conversion reagent is used for performing sulfite conversion on the purified partial human DNA, and is used for subsequent BMP3 and NDRG4 gene methylation detection. Through detecting two kinds of indexes of DNA and fecal occult blood in the faeces sample in a combined way, the kit provided by the invention is used for the early stage screening of the colorectal cancer. Compared with an FOBT (fecal occult blood test) detection method, the kit provided by the method can realize higher sensitivity on the detection of colorectal cancer, particularly the developing period tumor.

The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

The invention discloses a kit for synchronously detecting thirty diarrhea pathogens and a detection method of the kit. The kit comprises DEPC (diethylpyrocarbonate) water, a 5*RT (reverse transcription) buffer, a reverse transcription primer, a reverse transcriptase, an X solution, a 10*PCR (polymerase chain reaction) buffer, a PCR primer, a 25mM magnesium chloride solution, a DNA (deoxyribonucleic acid) polymerase and a positive control, and is characterized in that the reverse transcription primer comprises RT amplification primers of eleven diarrhea RNA viruses and a human RNA (ribonucleic acid) internal reference, and has a gene sequence shown as SEQ ID NO. 1-12 (sequence identifier number 1-12), and the PCR primer comprises forward and reverse PCR amplification primers of the rest nineteen diarrhea pathogens, a human DNA internal reference and a reaction internal reference, and PCR amplification primers of eleven diarrhea RNA viruses and the human RNA internal reference, and has a gene sequence shown as SEQ ID NO. 13-66. The kit and the detection method have the advantages of high specificity, sensitivity, flux and reliability, low cost, and no false negative results.

The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses intermediates useful for making the pyrimidone compounds. Additionally, pharmaceutical compositions and methods for treating those infected with HIV are encompassed.

The invention relates to a composite amplification kit of 47 human autosome and Y chromosome loci and an application thereof. The invention provides a composite amplification system of the 47 human autosome and Y chromosome loci, which comprises specific primers for amplifying the 47 loci, wherein the 47 loci comprise 19 autosome STR loci, 27 Y chromosome STR loci and 1 sex recognition locus. The47 pairs of specific primers are subjected to grouping fluorescence labeling by utilizing a six-color fluorescence labeling technology, and the simultaneous high-efficiency, specific and sensitive amplification of the 47 human autosome and Y chromosome loci is achieved through the design and optimization of primer sequences and working concentrations. The detection result of the composite amplification system has high individual identification capability and good data compatibility, and can be used for paternity identification and individual identification in practice, so that the detection cost of human DNA typing is effectively reduced, and the detection working efficiency is improved.

The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals having a colorectal neoplasm by detecting the presence of exfoliated epithelial markers (e.g., human DNA, tumor associated gene alterations, tumor associated proteins) and blood markers (e.g., homoglobin, serum proteins) in a stool sample obtained from the mammal.

An easy-to-use, versatile, disposable, customer-replaceable, multi-use, DNA sample collection disk apparatus for use with fixed, portable, or field-based DNA sample collection, analysis, and detection systems is disclosed. General features of the invention are its' small form factor, portability, wearability, ease-of-use, and self-contained capacity to collect and analyze multiple different human DNA samples and sample types. The special utility of the invention is demonstrated in the field wherein neither trained medical personnel, nor conventional DNA testing labs, are necessary to operate the invention. Invention preferred embodiments include multipurpose cards or badges designed to (1) electronically authenticate subjects identities using DNA samples, and/or electronically detect presence or absence of biological agents (e.g., anthrax) and/or chemical agents (e.g., Sarin) using DNA samples; and (2) perform other DNA-based, protein-based, or other analytic and/or identification functions.

The invention discloses a kit for synchronously detecting twenty-two respiratory tract pathogens and a detection method of the kit. The kit comprises DEPC (diethylpyrocarbonate) water, a 5*RT (reverse transcription) buffer, a reverse transcription primer, a reverse transcriptase, an X solution, a 10*PCR (polymerase chain reaction) buffer, a PCR primer, a 25mM magnesium chloride solution, a DNA (deoxyribonucleic acid) polymerase and a positive control, and is characterized in that the reverse transcription primer comprises RT amplification primers of the nine respiratory tract pathogens, and a reverse primer of a human RNA (ribonucleic acid) internal reference, and has a gene sequence shown as SEQ ID NO. 1-6 (sequence identifier number 1-6), and the PCR primer comprises forward and reverse PCR amplification primers of the rest thirteen respiratory tract pathogens, a forward and reverse amplification primer of a human DNA internal reference, a forward and reverse PCR amplification primer of a reaction internal reference, PCR amplification primers of the nine respiratory tract pathogens, and a PCR amplification primer of the human RNA internal reference, and has a gene sequence shown as SEQ ID NO. 7-44. The kit and the detection method have the advantages of high specificity, sensitivity, flux and reliability, low cost, and no false negative results.

The invention discloses a kit for synchronously detecting fifteen hemorrhagic fever pathogens and a detection method of the kit. The kit comprises DEPC (diethylpyrocarbonate) water, a 5*RT (reverse transcription) buffer, a reverse transcription primer, a reverse transcriptase, an X solution, a 10*PCR (polymerase chain reaction) buffer, a PCR primer, a 25mM magnesium chloride solution, a DNA (deoxyribonucleic acid) polymerase and a positive control, and is characterized in that the reverse transcription primer comprises RT amplification primers of the nine hemorrhagic fever pathogens and a human RNA (ribonucleic acid) internal reference, and has a gene sequence shown as SEQ ID NO. 1-10 (sequence identifier number 1-10), and the PCR primer comprises forward and reverse PCR amplification primers of the rest six hemorrhagic fever pathogens, a human DNA internal reference and a reaction internal reference, and PCR amplification primers of the nine hemorrhagic fever pathogens and the human RNA internal reference, and has a gene sequence show as SEQ ID NO. 10-36. The kit and the detection method have the advantages of high specificity, sensitivity, flux and reliability, low cost, and no false negative results.

A region of the Trichomonas vaginalis AP65-1 gene has been identified which is useful for performing amplification assays to determine specifically whether T. vaginalis is present in the sample being tested. Oligonucleotides useful for performing thermal Strand Displacement Assay (tSDA) reactions on this gene are disclosed. The disclosed oligonucleotides can be used in an assay which is specific for multiple strains of T. vaginalis and which does not show cross reactivity with the genomes of other microorganisms or with human DNA.

The invention belongs to the field of biotechnology, and specifically relates to a method for extracting human free DNA and a kit thereof, including magnetic bead pretreatment liquid, cell lysate, binding liquid, rinsing liquid I, rinsing liquid II, nucleic acid eluting liquid and carboxylation For magnetic beads, the binding solution includes components at the following concentrations: 0.1-0.3 mmol/L polysorbate 80 degradation product, 12-26 mmol/L polyethylene glycol 8000 and 1-2 mmol/L sodium chloride. The extraction efficiency, extraction purity and CT value of the kit of the invention are significantly better than those of the existing kits, and have the advantages of low cost and easy operation.

The invention provides a fluorescence PCR detection kit for human K-RAS gene mutation. The kit comprises a forward primer sequence K-M1 PCR reaction solution, a forward primer sequence K-M2 PCR reaction solution, a forward primer sequence K-M3 PCR reaction solution, a forward primer sequence K-M4 PCR reaction solution, a forward primer sequence K-M5 PCR reaction solution, a forward primer sequence K-M6 PCR reaction solution and a forward primer sequence K-M7 PCR reaction solution which are used for detecting Gly12Asp mutation, Gly12Val mutation, Gly12Ser mutation, Gly12Cys mutation, Gly12Ala mutation, Gly12Arg mutation and Gly13Asp mutation on a codon 12 and codon 13. According to the kit, under the 100ng/reaction wild-type human DNA background, amplification signals and the false positive condition are avoided, and it shows that the kit is good in specificity and high in antijamming capability. By the adoption of the kit, human K-RAS gene mutation in samples such as clinical paraffin sections can be detected quickly, and a reliable experiment basis is provided for diagnosing related cancer therapies.